{
    "clinical_study": {
        "@rank": "116200", 
        "brief_summary": {
            "textblock": "The purpose of this study is to see if it is safe and effective to give Viracept to AIDS\n      patients who are already being treated for cytomegalovirus (CMV) retinitis."
        }, 
        "brief_title": "A Study of Viracept in AIDS Patients With Cytomegalovirus Retinitis", 
        "condition": [
            "Cytomegalovirus Retinitis", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Retinitis", 
                "Cytomegalovirus Retinitis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  HIV infection.\n\n          -  Newly diagnosed or first progression of CMV retinitis.\n\n        Exclusion Criteria\n\n        Prior Medication:\n\n        Excluded:\n\n        Prior therapy (or less than 2 weeks) with protease inhibitor other than saquinavir."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "13 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002169", 
            "org_study_id": "259A", 
            "secondary_id": [
                "Study 517", 
                "AG1343-517"
            ]
        }, 
        "intervention": {
            "intervention_name": "Nelfinavir mesylate", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Nelfinavir"
        }, 
        "keyword": [
            "AIDS-Related Opportunistic Infections", 
            "Placebos", 
            "Antiviral Agents", 
            "Cytomegalovirus Retinitis", 
            "Treatment Outcome", 
            "Nelfinavir"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90033"
                    }, 
                    "name": "Univ of Southern California / LA County USC Med Cntr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orange", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92868"
                    }, 
                    "name": "Univ of California / UCI Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92103"
                    }, 
                    "name": "Univ of California / San Diego Treatment Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Torrance", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90502"
                    }, 
                    "name": "Harbor UCLA Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "District of Columbia", 
                        "zip": "20037"
                    }, 
                    "name": "George Washington Univ"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60611"
                    }, 
                    "name": "Northwestern Univ / SOCA"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Galveston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77555"
                    }, 
                    "name": "Univ of Texas Med Branch"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77009"
                    }, 
                    "name": "Baylor Univ"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase II, Randomized, Placebo-Controlled Study to Determine the Effects of Viracept on the Clinical Outcome of Cytomegalovirus (CMV) Retinitis in AIDS Patients Who Are Receiving Standard Induction and Maintenance Therapy for This Infection", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002169"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Agouron Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 1999"
    }, 
    "geocoordinates": {
        "Baylor Univ": "29.76 -95.369", 
        "George Washington Univ": "38.895 -77.036", 
        "Harbor UCLA Med Ctr": "33.836 -118.341", 
        "Northwestern Univ / SOCA": "41.878 -87.63", 
        "Univ of California / San Diego Treatment Ctr": "32.715 -117.157", 
        "Univ of California / UCI Med Ctr": "33.788 -117.853", 
        "Univ of Southern California / LA County USC Med Cntr": "34.052 -118.244", 
        "Univ of Texas Med Branch": "29.301 -94.798"
    }
}